Abivax (ABVX) reported full-year 2025 net loss late Monday of 336.1 million euros ($390.4 million), widening from a loss of 176.2 million euros a year earlier.
As of Dec. 31, the company had cash and cash equivalents of 530.4 million euros, expected to fund operations into Q4 2027.
Sofinnova Partners, represented by Kinam Hong, stepped down from the board last week, the company added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments